UNSPSC 51313304: Promethazine hydrobromide

This classification denotes a phenothiazine C17H20N2S.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H7Q13127S, chemically known as 10h-phenothiazine-10-ethanamine, n,n,.alpha.-trimethyl-, hbr (1:1), but more generally known as promethazine hydrobromide, which bears US NIH Compound Identifier 56841706. Most nations, for tariff and trade purposes, schedule promethazine hydrobromide under HS 29343090 and SITC 51578. As of Q4 2014, PROMETHAZINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity.

Promethazine hydrobromide bears US NLM identifiers UMLS ID C0982361 and NCI Concept Code C97704. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)N(C)C.BR.

UNSPSC 51313304 Promethazine hydrobromide is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The single recent opportunity identified under this code—Seminole County, Florida's IFB 60459723LAS—is actually soliciting naloxone and drug deactivation systems for community health initiatives, not promethazine hydrobromide. The mismatch signals either a coding error in the county's procurement system or a broader misclassification; the sourced data does not support active state and local buying of promethazine hydrobromide at this time.

Seminole County's naloxone and deactivation-systems procurement is the only recent state or local opportunity on record under this code. The IFB, posted June 30, 2026, with a response deadline of July 26, 2023, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract includes a two-year initial term with a one-year renewal option, E-Verify and drug-free workplace certification requirements, and potential FEMA funding with associated federal compliance obligations. Given the code's weak activity profile and the disconnect between the code name and actual procurement, this category does not present a clear pursuit opportunity for vendors in the promethazine market.